Nanjing Hicin Pharmaceutical Co., Ltd.

Nanjing Hicin Pharmaceutical Co., Ltd. is a pharmaceutical manufacturing company listed on the ChiNext board of the Shenzhen Stock Exchange since 2017. The company, along with its subsidiaries, focuses on the research and development, production, and sales of chemical preparations, active pharmaceutical ingredients, and intermediates. Its diverse product range addresses various treatment areas, including cardiovascular and cerebrovascular diseases, anti-infection, digestive system issues, and more, with a commitment to developing innovative and high-quality products that have clinical value. The company boasts significant advantages in research and development, with a dedicated team and advanced scientific research equipment. It holds 79 approval numbers for its products, which include over 20 active pharmaceutical ingredients and preparations. Nanjing Hicin has established a robust marketing network that spans major provinces and cities in China, supported by over 1,000 distributors and sales to approximately 3,000 hospitals. The company also benefits from industrial synergy through its wholly-owned and holding subsidiaries, which enhance its supply chain management and resource integration capabilities within the pharmaceutical sector.

1. Advantage in R&D capabilities The company adheres to the core strategy of new drug research and development for its growth. Since its establishment, it has set up a research and development center, with over 60 R&D personnel dedicated to drug research and development. The company is equipped with advanced domestic scientific research equipment and analytical instruments, and has established a complete R&D system. The company and its affiliated parties are still significant shareholders of the NMS Group at present. 2. Product category advantages The company currently holds 79 approval numbers for active pharmaceutical ingredients and preparations, with over 20 products in operation all year round. The products cover multiple fields such as cardiovascular and cerebrovascular drugs, antibiotics, diuretics, digestive drugs, antiviral drugs, and immunomodulatory drugs. 3. Advantages in drug quality The company attaches great importance to product quality and has always adhered to the quality policy of "Quality First, Full Participation, Risk Management, standardized production, continuous improvement, and Safe Medication Use". 4. Advantages of marketing network At present, the company's marketing network has covered major provinces and provincial capitals, as well as key cities with independent planning status across the country. It has over 1,000 distributors nationwide, and its products are sold in approximately 3,000 hospitals at or above the county level. 5. Industrial synergy advantages The wholly-owned subsidiaries Zhenjiang Derui and Anhui Haichen, as well as the holding subsidiary Anqing Huichen, are important strategic layouts for the company to achieve industrial chain synergy and integration. They not only ensure the sufficient supply of raw materials for various varieties of the company's subsequent product lines but also strengthen the company's management of raw material prices and product gross profit margins, reducing the potential risks brought by the future supply chain to the company's operations. It has profound significance for the company's layout of the entire industrial chain of chemical pharmaceuticals and battery materials. 6. Advantage of resource integration The company's founder, senior executives and expert team have been deeply involved in the pharmaceutical industry for over three decades. They possess a professional background in the pharmaceutical field, have a keen insight and judgment into the industry's development trends, and have rich resources and information advantages in the pharmaceutical industry. They are capable of integrating resources in line with industry policies and market changes to formulate the company's development strategy.